BOSTON - Scientists are making progress in using less toxic immunotherapy instead of traditional chemotherapy to fight cancer ...

VIENNA, Va., April 23, 2024 -- ( BUSINESS WIRE )--CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of ...

development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation ...

Multikine (Leukocyte Interleukin, Injection) received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. The Company ...

"If licensed, LI [Multikine] will offer the first-line neoadjuvant treatment in previously untreated ... new standard of care for head and neck cancer. This is a big step forward in the UK ...

The program of therapy prescribed for you depends on several factors including: tumor size, lymph node status, cell type, hormone receptor tests, cell growth patterns, your age and health, menopausal ...

With quality of life as important as a cure, focal therapies like HIFU, high-intensity focused ultrasound, and Nanoknife, ...

Ice could be the next frontier in breast cancer therapy, according to new research from Memorial Sloan Kettering Cancer Center in New York. In breast cancer patients, cold therapy was shown to be ...

Gagandeep Brar, MD, is a board-certified hematologist and medical oncologist. Her research interest is in gastrointestinal malignancies with a focus on immune and targeted therapies. Prostate ...

fighting cancer began with his family Cancer treatment was for years dominated by just four techniques. But there is now a fifth category -- immunotherapy -- thanks to the revolutionary research ...

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States.